The promises of quantitative systems pharmacology modelling for drug development

Recent growth in annual new therapeutic entity (NTE) approvals by the U.S. Food and Drug Administration (FDA) suggests a positive trend in current research and development (R&D) output. Prior to this, the cost of each NTE was considered to be rising exponentially, with compound failure occurring...

Descripción completa

Detalles Bibliográficos
Autores principales: Knight-Schrijver, V.R., Chelliah, V., Cucurull-Sanchez, L., Le Novère, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2016
Materias:
Short Survey
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064996/
https://www.ncbi.nlm.nih.gov/pubmed/27761201
http://dx.doi.org/10.1016/j.csbj.2016.09.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064996/
https://www.ncbi.nlm.nih.gov/pubmed/27761201
http://dx.doi.org/10.1016/j.csbj.2016.09.002

Ejemplares similares